Return of results in cancer research

Overview #

Return of results refers to the communication of research findings to the people who contributed to a study, including patients with cancer, cancer survivors, healthy volunteers, and donors of biological samples or data.  

In cancer research, return of results is particularly important because molecular profiling, tumour sequencing, genetic analysis, imaging, etc. can generate information that may be relevant to diagnosis, treatment, prevention, family members, or future health.

However, it is important to underline that returning a research result is not the same as providing a clinically validated diagnosis. A finding generated in a research laboratory may be uncertain, or unsuitable for clinical decision-making until confirmed through an appropriate clinical pathway.

Types of results #

The term “Return of Results” can cover distinct things that raise different ethical and legal questions:

  • Individual research results (IRR): findings about a specific participant that were the aim of the study (for example a polygenic risk score)
  • Incidental findings (IF): findings not directly sought by the research protocol but discovered during analysis, typically germline pathogenic variants found while sequencing tumour and/or normal DNA and associated with inherited cancer susceptibility
  • Secondary findings: findings deliberately sought beyond the research question, such as the variants in genes associated with hereditary cancer predisposition
  • Aggregate (study-level) results: overall outcomes of a study or clinical trial, such as new insights into tumour biology, usually communicated through lay summaries, newsletters or websites. These are generally not linked to an individual participant.

Why cancer research is distinctive #

  • Somatic and germline interplay. Tumour sequencing, especially when a matched normal sample is used, can reveal hereditary cancer predisposition with implications for the participant and blood relatives.
  • Participants are often patients. The boundary between research and care is blurred. Participants may expect results to guide treatment (therapeutic misconception) and clinicians may want research results for molecular tumour boards.
  • Time sensitivity. In advanced disease, results may only be useful if returned quickly, which conflicts with research timelines, validation and ethics review.

Main policy approaches #

Policy positions are usually described as a spectrum:

  • Minimal or no return: research is not clinical care, and researchers have no duty to return individual results beyond exceptional cases;
  • Qualified or conditional return (the dominant international position): return findings that meet criteria such as analytic validity, clinical validity, clinical utility or actionability, and participant preference;
  • Broad return on request: return a wider range of results, including those of uncertain or personal utility, if the participant chooses and the study can support it.

Common criteria for return are the following:

  1. the finding is analytically valid, ideally confirmed in an accredited laboratory;
  2. it is clinically valid and associated with a significant health risk;
  3. it is actionable or has established clinical or reproductive relevance;
  4. the participant was informed in the consent process and, where applicable, chose to receive or decline results;
  5. resources exist for counselling and referral.

A return-of-results policy should be developed before research begins, incorporated into the consent process, reviewed through appropriate governance, and supported by realistic plans for validation, communication, and follow-up. 

Return policy must:

  • Respect participants’ autonomy, including their preferences about whether to receive individual findings.
  • Communicate meaningful research progress to participants and the wider public.
  • Offer potentially important health information when justified by its validity, clinical significance, and the applicable legal and ethical framework.
  • Avoid harm from inaccurate, ambiguous, or misunderstood results.
  • Establish clear responsibilities among researchers, biobanks, laboratories, clinicians, sponsors, and ethics committees.
  • Build trust, reciprocity, and transparency in cancer research.

Ethical, legal and social implications (ELSI) #

Autonomy and the right to know or not to know #

Participants may want information that could influence their treatment or reproductive choices, or family planning. Others may prefer not to receive uncertain findings or information about inherited cancer risk.

Consent should explain which categories of results may be returned, which will not be returned, whether participants can opt in or out, and whether preferences can be changed.   

Scientific validity and clinical actionability #

Research findings vary in reliability and usefulness. Before an individual finding is communicated as medically meaningful, the project should consider:

  • Analytical validity: Is the finding reliably detected by the method used?
  • Clinical validity: Is the association between the finding and a health outcome sufficiently established?
  • Clinical actionability: Is there an established intervention, preventive measure, surveillance pathway, or other meaningful action?
  • Clinical confirmation: Is confirmatory testing in an appropriately accredited or clinically validated laboratory necessary before clinical decisions are made?

Incidental findings and hereditary cancer risk #

Cancer genomics may reveal germline variants associated with hereditary cancer syndromes, potentially affecting relatives as well as the participant. Ethical questions include whether to return such findings, who should communicate them, how to arrange genetic counselling, and whether or how relatives should be informed.

Policies should define criteria for assessing findings, assigning responsibility for review, confirming results, contacting participants, and providing appropriate referral pathways. They should also account for participants who cannot be re-contacted or who previously declined results.

Psychological and social consequences #

Receiving information about cancer risk or uncertain genetic findings may cause anxiety, distress, false reassurance, family conflict, or changes in perceived identity. There may also be concerns about stigma, discrimination, privacy, and the possible future use of genetic information.

Communication should therefore be proportionate to the significance and certainty of the finding, use accessible language, and provide routes to professional support where appropriate.

Privacy, confidentiality and data protection #

Individual findings may contain sensitive health and genetic information. Re-contacting a participant can itself reveal involvement in a study or a health concern. Projects should define who may access identifiable data, how re-identification will be authorised, how information will be securely transmitted, and what will be recorded in clinical records.

Genetic findings may also reveal information about biological relatives. The privacy interests of the participant and their relatives should be considered without assuming that a research team has an automatic right or duty to disclose information directly to family members.

Equity and justice #

Return of results can create inequities if only participants with access to specialist centres, genetic counselling, confirmatory testing, or follow-up care can benefit. Language barriers, disability, health literacy, geographical distance, and socioeconomic disadvantage may also affect access.

Projects should consider accessible communication, translation, appropriate referral arrangements, and the distribution of the costs of confirmation and follow-up. The possibility of returning results should not be overstated where the necessary clinical services are unavailable.

Research responsibilities and operational feasibility #

Returning individual findings requires infrastructure, trained personnel, re-contact mechanisms and follow-up. Responsibilities may be distributed across a principal investigator, biobank, laboratory, clinical team, sponsor, and data controller.

Projects should specify who evaluates a finding, who authorises its return, who contacts the participant, what happens if the participant is no longer under the care of the original institution. A blanket policy to return every finding may be inappropriate; decisions should be justified by the study context and established in advance.

Legal and ethical international and EU sources #

There is no single EU-wide rule that requires every cancer research project to return all individual research results. Data protection rights, research ethics, national law, clinical laboratory requirements must be considered together.

International ethical sources #

  • WMA Declaration of Helsinki (2024 revision): relevant to informed consent and transparency
  • WMA Declaration of Taipei (2016): Particularly relevant to cancer biobanks and secondary use of samples and data. It explicitly identifies procedures for returning results, including incidental findings, as information that should be addressed in consent for databases and biobanks. The Declaration is undergoing a revision process initiated in 2025.
  • CIOMS International Ethical Guidelines (2016):  relevant to developing a proportionate policy for communicating individual findings.

European Union legal framework #

External resources #

Relevant literature #

  • Roberts JS, Shalowitz DI, Christensen KD, Everett JN, Kim SY, Raskin L, Gruber SB. Returning individual research results: development of a cancer genetics education and risk communication protocol. J Empir Res Hum Res Ethics. 2010 Sep;5(3):17-30. doi: 10.1525/jer.2010.5.3.17. PMID: 20831418; PMCID: PMC3159194.
  • O’Byrne SM, Castaneda I, Collins R-N, et al. Return of results is important to heterogeneous research participants: A single-site survey. Journal of Clinical and Translational Science. 2026;10(1):e67. doi:10.1017/cts.2026.10716
  • Bethany M. Kwan, Juliana G. Barnard, Carly Ritger, Elizabeth W. Staton, Ifeoma Perkins, Ricardo Gonzalez-Fisher, Lindsay A. Lennox, Nestelynn Gay, Kevin C. Johnson, Roel G.W. Verhaak, Elizabeth B. Claus, Matthew DeCamp, Liz Salmi, Community perspectives on the return of research results and ownership of data and specimens for brain tumor genomic research, SSM – Qualitative Research in Health, Volume 9, 2026, 100741, ISSN 2667-3215, https://doi.org/10.1016/j.ssmqr.2026.100741
  • Best, M.C., Bartley, N., Napier, C.E. et al. Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study. Support Care Cancer 30, 8201–8210 (2022). https://doi.org/10.1007/s00520-022-07272-3
  • Johns, A. L. et al. (2017) Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Medicine, 9, 41. (doi: 10.1186/s13073-017-0430-4) (PMID:28454591) (PMCID:PMC5408494)
  • Heinz-Josef Lenz, David W Craig, Kevin C Johnson, Roel Verhaak, Oindrila Bhattacharyya, Bethany Davis, Cherie Wesley, Sara A Byron, Cheryl Willman, Lindsey Kelley, Elizabeth B Claus, Jeffrey Trent, Julie O Culver, Stacy W Gray, Alanna J Church, Challenges in the return of molecular tumor profiling results, JNCI: Journal of the National Cancer Institute, Volume 118, Issue 5, May 2026, Pages 776–782, https://doi.org/10.1093/jnci/djaf251
  • Johnson KJ, Gehlert S. Return of Results from Genomic Sequencing: A Policy Discussion of Secondary Findings for Cancer Predisposition. J Cancer Policy. 2014 Sep 1;2(3):75-80. doi: 10.1016/j.jcpo.2014.05.001. PMID: 25229012; PMCID: PMC4163150.
  • Best, M.C., Butow, P., Savard, J. et al. Preferences for return of germline genome sequencing results for cancer patients and their genetic relatives in a research setting. Eur J Hum Genet 30, 930–937 (2022). https://doi.org/10.1038/s41431-022-01069-y

Acknowledgements #

The work done stems from research conducted in the context of two projects:

  • project canSERV – Providing Cutting-Edge Cancer Research Services Across Europe, which has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant agreement ID: 101058620. The project started on 1 September 2022 and ended on 31 August 2026, then extended until 28 February 2027. 
  • PERIFORMANCE project (PUBLIC ENGAGEMENT IN RESEARCH INFRASTRUCTURES FOR MISSION CANCER: MANAGING COMPLEXITY OF EMERGING TECHNOLOGIES), Grant agreement ID: 101216808, started on 1 September 2025 and to be finished by 31 August 2028.

Updated on 16 November, 2026
WordPress Cookie Notice by Real Cookie Banner